Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PBS Vax HCV Vaccine
- Development stage
- Preclinical
- Lead developer
- Auro Vaccines
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
PBS Vax HCV Vaccine is a therapeutic vaccine candidate developed by Auro Vaccines for the treatment of chronic Hepatitis C virus (HCV) infection. The vaccine utilizes a heterologous prime-boost strategy, combining a GeneVax DNA vaccine prime with a VesiculoVax viral vector boost. The VesiculoVax platform is based on a recombinant vesicular stomatitis virus (rVSV) vector. This approach is designed to elicit a broad and potent immune response, including both cellular (T-cell) and humoral (antibody) components, against HCV antigens across all major genotypes. The goal of the therapy is to achieve viral clearance in chronically infected individuals. As of the latest pipeline information, the program is in the preclinical stage and is currently listed as being on hold.
- Brand names
- PBS Vax
- Other names
- HCV vaccineGeneVax prime / VesiculoVax boost HCV vaccinePBS Vax HCV Vaccine
02
Targets
Hepatitis C virus peptide–major histocompatibility complexIL-12R (Interleukin-12 receptor)Hepatitis C virus-specific T-cell receptor (HCV-specific TCR)HCV E2 (Hepatitis C virus envelope glycoprotein E2)
Beyond the preview
Go deeper on PBS Vax HCV Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PBS Vax HCV Vaccine.